|
Pear Therapeutics, Inc.
Ticker Symbol: PEARQ* CUSIP: 704723105 Exchange: OTOTC
* NOTE: This security is no longer trading as of 5/28/2024
Company's Online Profile
BUSINESS: Pear Therapeutics, Inc. is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.
|
Find All Related Securities for PEARQ*
Notes: April 07, 2023 -- Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the “Debtors”) each voluntarily filed for protection under chapter 11 (“Chapter 11”) of the U.S. Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.
|
IPO - 2/2/2021 -
Link to IPO Prospectus
Previous Ticker Symbol: PEAR Changed: 4/17/2023
Previous Name: Thimble Point Acquisition Corp Changed: 12/03/2021
Small Cap Stock -
Market Value $ Million
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 200 State Street, 13th Floor, Boston, MA 02109 |
| Main Phone Number |
617-925-7848 |
| Fax Number |
Not Available |
| Corporate Communications
Meara Murphy
|
617-925-7848
|
| CEO - Elon S. Boms |
CFO - Christopher Guiffre |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
